1. A pharmaceutical product comprising (i) a first composition comprising as active agent vemurafenib or a pharmaceutically acceptable salt thereof, and (ii) a second composition comprising as active agent MDM2 inhibitor or a pharmaceutically acceptable salt thereof, as a combined preparation for simultaneous or sequential use in the treatment of cancer wherein the amount of said active agent provides a combination of therapeutic efficacy in the treatment raka.2. A pharmaceutical product according to Claim. 1, wherein the first composition and the second composition are administered posledovatelno.3. A pharmaceutical product according to Claim. 1, wherein the first composition is administered simultaneously with the second kompozitsiey.4. A pharmaceutical product according to Claim. 1, wherein the first and second compositions are in a dosage forme.5. A pharmaceutical product according to Claim. 1 for use as a medicament in treating cancer, positive for b-Raf mutation V600, preferably tumor mutation V600E.6. A pharmaceutical product according to claim. 5, wherein said cancer is selected from the group consisting of cancer of the colon and rectum, melanomas, sarcomas and thyroid cancers, wherein said cancer comprises a tumor bearing b-Raf mutation V600E.7. A pharmaceutical product according to Claim. 1 wherein vemurafenib or a pharmaceutically acceptable salt thereof is administered in an amount from about 200 mg / day to about 3000 mg / sut.8. A pharmaceutical product according to Claim. 1 wherein vemurafenib or a pharmaceutically acceptable salt thereof is administered in an amount from about 960 mg / day to about 2000 mg / sut.9. A pharmaceutical product according to any one of claims. 1-8, wherein said MDM2 inhibitor is Compound (III) formulyfar1。一种药物产品,包括(i)第一组合物,该第一组合物包含作为活性剂维莫拉非尼或其药学上可接受的盐,以及(i i)第二组合物,该第二组合物包含作为活性剂MDM2抑制剂或其药学上可接受的盐,作为同时或顺序用于治疗癌症的联合制剂,其中所述活性剂的量在治疗raka中提供了治疗效果的组合。根据权利要求的药物产品。1,其中第一组分和第二组分给予PasdodoVaTelNO 3。根据权利要求的药物产品。1,其中第一组合物与第二KoPoZisisiy同时施
